- Home
- SANG vs SLS Comparison
SANG vs SLS Comparison
Compare SANG & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANG
- SLS
- Stock Information
- Founded
- SANG 1984
- SLS 2012
- Country
- SANG Canada
- SLS United States
- Employees
- SANG N/A
- SLS N/A
- Industry
- SANG Computer Software: Programming Data Processing
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- SANG Technology
- SLS Health Care
- Exchange
- SANG Nasdaq
- SLS Nasdaq
- Market Cap
- SANG 189.6M
- SLS 169.6M
- IPO Year
- SANG 2021
- SLS N/A
- Fundamental
- Price
- SANG $6.00
- SLS $2.05
- Analyst Decision
- SANG
- SLS
- Analyst Count
- SANG 0
- SLS 0
- Target Price
- SANG N/A
- SLS N/A
- AVG Volume (30 Days)
- SANG 2.7K
- SLS 3.3M
- Earning Date
- SANG 05-08-2025
- SLS 08-12-2025
- Dividend Yield
- SANG N/A
- SLS N/A
- EPS Growth
- SANG N/A
- SLS N/A
- EPS
- SANG N/A
- SLS N/A
- Revenue
- SANG $238,264,000.00
- SLS N/A
- Revenue This Year
- SANG N/A
- SLS N/A
- Revenue Next Year
- SANG $2.91
- SLS N/A
- P/E Ratio
- SANG N/A
- SLS N/A
- Revenue Growth
- SANG N/A
- SLS N/A
- 52 Week Low
- SANG $4.08
- SLS $0.77
- 52 Week High
- SANG $7.99
- SLS $2.22
- Technical
- Relative Strength Index (RSI)
- SANG 60.10
- SLS 64.79
- Support Level
- SANG $5.61
- SLS $1.50
- Resistance Level
- SANG $6.37
- SLS $2.22
- Average True Range (ATR)
- SANG 0.11
- SLS 0.15
- MACD
- SANG 0.02
- SLS 0.05
- Stochastic Oscillator
- SANG 54.88
- SLS 81.81
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.